{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:32:46Z","timestamp":1785929566795,"version":"3.56.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"DOI":"10.7759\/cureus.71511","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T09:23:27Z","timestamp":1728984207000},"source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of Semaglutide Use in Achieving Target Body Mass Index Before Renal Transplant in Five End-Stage Renal Disease Patients: A Case Series"],"prefix":"10.7759","author":[{"given":"Naeem","family":"Al-saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurang Hasmukhbhai","family":"Suhagiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badar Ud Din","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahanzeb","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad Jawad","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15784","article-title":"Obesity, transplantation, and bariatric surgery: an evolving solution for a growing epidemic","volume":"20","author":"Diwan TS","year":"2020","unstructured":"Diwan TS, Lee TC, Nagai S, et al.. Obesity, transplantation, and bariatric surgery: an evolving solution for a growing epidemic. Am J Transplant. 2020, 20:2143-55. 10.1111\/ajt.15784","journal-title":"Am J Transplant"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2015.0295","article-title":"Consequences of recipient obesity on postoperative outcomes in a renal transplant: a systematic review and meta-analysis","volume":"14","author":"Sood A","year":"2016","unstructured":"Sood A, Hakim DN, Hakim NS. Consequences of recipient obesity on postoperative outcomes in a renal transplant: a systematic review and meta-analysis. Exp Clin Transplant. 2016, 14:121-28. 10.6002\/ect.2015.0295","journal-title":"Exp Clin Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran P","year":"2011","unstructured":"Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011, 365:1597-604. 10.1056\/NEJMoa1105816","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah M","year":"2014","unstructured":"Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord. 2014, 15:181-7. 10.1007\/s11154-014-9289-5","journal-title":"Rev Endocr Metab Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0649-2","article-title":"Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment","volume":"57","author":"Granhall C","year":"2018","unstructured":"Granhall C, S\u00f8ndergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018, 57:1571-80. 10.1007\/s40262-018-0649-2","journal-title":"Clin Pharmacokinet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD- 7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle KR","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, et al.. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD- 7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018, 6:605-17. 10.1016\/S2213-8587(18)30104-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.110.034066","article-title":"Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase","volume":"38","author":"Malm-Erjef\u00e4lt M","year":"2010","unstructured":"Malm-Erjef\u00e4lt M, Bj\u00f8rnsdottir I, Vanggaard J, et al.. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010, 38:1944-53. 10.1124\/dmd.110.034066","journal-title":"Drug Metab Dispos"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like Peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen JJ","year":"2022","unstructured":"Chen JJ, Wu CY, Jenq CC, et al.. Association of glucagon-like Peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease. JAMA Netw Open. 2022, 5:e221169. 10.1001\/jamanetworkopen.2022.1169","journal-title":"JAMA Netw Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac090","article-title":"Semaglutide for treatment of obesity in hemodialysis patients waiting for a kidney transplant: new hope?","volume":"15","author":"Touzot M","year":"2022","unstructured":"Touzot M, Ure\u00f1a-Torres P, Dupuy O. Semaglutide for treatment of obesity in hemodialysis patients waiting for a kidney transplant: new hope?. Clin Kidney J. 2022, 15:1782-4. 10.1093\/ckj\/sfac090","journal-title":"Clin Kidney J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2020.0829","article-title":"Bariatric surgery and long-term survival in patients with obesity and end-stage kidney disease","volume":"155","author":"Sheetz KH","year":"2020","unstructured":"Sheetz KH, Gerhardinger L, Dimick JB, Waits SA. Bariatric surgery and long-term survival in patients with obesity and end-stage kidney disease. JAMA Surg. 2020, 155:581-8. 10.1001\/jamasurg.2020.0829","journal-title":"JAMA Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/nep.14277","article-title":"Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease","volume":"29","author":"Wallace R","year":"2024","unstructured":"Wallace R, Hamblin PS, Tully E, Tran J, Nelson C, Levidiotis V. Case report of the successful use of semaglutide to achieve target BMI prior to renal transplant in two patients with end-stage-kidney-disease. Nephrology (Carlton). 2024, 29:371-4. 10.1111\/nep.14277","journal-title":"Nephrology (Carlton)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000527919","article-title":"Efficacy and safety of semaglutide, a glucagon-like peptide-1 receptor agonist in real-life: a case series of patients in maintenance Incremental hemodialysis","volume":"12","author":"De la Flor JC","year":"2022","unstructured":"De la Flor JC, Lorenzo JD, Marschall A, Valga F, V\u00e1zquez TM, C\u00edcero ER. Efficacy and safety of semaglutide, a glucagon-like peptide-1 receptor agonist in real-life: a case series of patients in maintenance Incremental hemodialysis. Case Rep Nephrol Dial. 2022, 12:238-47. 10.1159\/000527919","journal-title":"Case Rep Nephrol Dial"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000642","article-title":"Multimorbidity patterns: obesity as the main modifiable risk factor in adult women in Southern Brazil","volume":"67","author":"Franken DL","year":"2023","unstructured":"Franken DL, Dias-da-Costa JS, Olinto MT, Sturmer J, Bordin RB, Paniz VM. Multimorbidity patterns: obesity as the main modifiable risk factor in adult women in Southern Brazil. Arch Endocrinol Metab. 2023, 67:e000642. 10.20945\/2359-3997000000642","journal-title":"Arch Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/288548-outcomes-of-semaglutide-use-in-achieving-target-body-mass-index-before-renal-transplant-in-five-end-stage-renal-disease-patients-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T09:23:28Z","timestamp":1728984208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/288548-outcomes-of-semaglutide-use-in-achieving-target-body-mass-index-before-renal-transplant-in-five-end-stage-renal-disease-patients-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.71511","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,15]]}}}